- Home
- MNPR vs BXC Comparison
MNPR vs BXC Comparison
Compare MNPR & BXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | BXC |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Wholesale Distributors |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.6M | 504.5M |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | MNPR | BXC |
|---|---|---|
| Price | $76.19 | $65.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $97.83 | $88.67 |
| AVG Volume (30 Days) | ★ 163.8K | 106.3K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.71 |
| Revenue | N/A | ★ $2,948,840,000.00 |
| Revenue This Year | N/A | $0.69 |
| Revenue Next Year | N/A | $3.13 |
| P/E Ratio | ★ N/A | $38.07 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.00 | $52.71 |
| 52 Week High | $105.00 | $126.45 |
Technical Indicators
Market Signals| Indicator | MNPR | BXC |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 58.45 |
| Support Level | $74.51 | $58.47 |
| Resistance Level | $79.31 | $61.98 |
| Average True Range (ATR) | 6.38 | 3.18 |
| MACD | -0.93 | 1.14 |
| Stochastic Oscillator | 6.10 | 89.40 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.